Screening of NASH in Oupatients Followed in Various Hospital Specialty Clinics at the University Hospital of Strasbourg

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-08-14

Study Completion Date

2022-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the present study is to assess, by using a simple algorithm combining FIB-4 and Fibroscan, the prevalence of NASH with advanced fibrosis in outpatients followed in various hospital specialty clinics other than hepato/gastroenterology and to examine risk factors associated with this condition. The prevalence of NASH will be investigated among 6 cohorts of outpatients followed in different hospital specialty clinics at Hôpitaux Universitaires de Strasbourg.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

SCREaning of Advanced Liver Fibrosis Using Non-Invasive Tests in General Population

NCT05880173

Screening Advanced Liver Fibrosis

RECRUITING NA

FIBROSCAN Validation and Interest of Fibrotest - FIBROSCAN Association for Fibrosis Diagnosis in Alcoholic Liver Disease

NCT00708617

Alcoholic Liver Disease

COMPLETED

Study of Liver Fibrosis Stage Assessment by Fibroblast Activation Protein Imaging in Patients With Biopsy for Suspected or Proven Nonalcoholic Steatohepatitis

NCT06160271

Non-alcoholic Steatohepatitis

NOT_YET_RECRUITING PHASE2

Study Visceral Adipose Tissue and Liver Stifness in a Retrospective Cohort of Diabetes Mellitus Patients

NCT04493814

NAFLD Type 2 Diabetes

UNKNOWN

Molecular Investigation of Non Alcoholic Fatty Liver Diseases in Obese Patients

NCT00844779

Liver Disease

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nonalcoholic Fatty Liver Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age ≥ 18 years
* outpatients followed at specialty clinics in HUS and at risk of NAFLD: with at least one metabolic risk factor (overweight, diabetes mellitus, hypertension, hypertriglyceridemia) and/or elevated transaminases and/or liver steatosis on US.
* endocrinology cohort : type 2 diabetes patients
* infectious disease cohort : HIV positive patients
* rheumatology cohort : patients with psoriasis, gout or rheumatoid arthritis
* nephrology cohort : patients with chronic kidney disease such as diabetic nephropathy or hypertensive nephropathy, including those receiving hemodialysis.
* cardiology cohorts: patients with history of angina, myocardial infarction, stroke or arteritis of lower limbs.
* internal medicine cohort: patients with auto immune systemic diseases such as lupus, sclerosis or rheumatoid arthritis.
* subjects who have given their informed consent
* Subjects affiliated to a social security system

Exclusion Criteria

* alcohol consumption \> 30g/d in male or \> 20g/d in female in the past 6 months
* history of chronic viral hepatitis
* history of liver auto immune disease, genetic hemochromatosis, Wilson disease
* biliary disease, bile duct obstruction
* drug-induced liver injury
* secondary liver cancer or other active cancer
* organ graft
* use of medications associated with secondary NAFLD (corticosteroids, tamoxifen, amiodarone, methotrexate).
* congestive heart failure
* AIDS
* pregnancy, breastfeeding
* no information could be given to the patient (subject faces emergency situation, comprehension difficulties, etc.)
* patient under guardianship
* patients under judicial protection

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No